Sarepta Therapeutics Enters Material Definitive Agreement
Ticker: SRPT · Form: 8-K · Filed: Nov 26, 2024 · CIK: 873303
Sentiment: neutral
Topics: material-definitive-agreement, new-deal
TL;DR
Sarepta just signed a big deal, details TBD.
AI Summary
On November 24, 2024, Sarepta Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.
Why It Matters
This filing signifies a potentially significant development for Sarepta Therapeutics, indicating a new contract or partnership that could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement, posing a medium risk until more information is available.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- November 24, 2024 (date) — Date of earliest event reported
- 215 First Street Suite 415 Cambridge , MA 02142 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Sarepta Therapeutics?
The filing states that Sarepta Therapeutics, Inc. entered into a material definitive agreement on November 24, 2024, but does not provide specific details about the agreement itself.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the material definitive agreement.
What is the effective date of this material definitive agreement?
The earliest event reported, which is the entry into the material definitive agreement, occurred on November 24, 2024.
Are there any financial terms or obligations associated with this agreement mentioned in the filing?
No specific financial terms or obligations related to the material definitive agreement are disclosed in this 8-K filing.
Does this agreement represent a new partnership, acquisition, or licensing deal for Sarepta Therapeutics?
The filing does not specify whether the material definitive agreement is a partnership, acquisition, licensing deal, or any other type of arrangement.
Filing Stats: 1,544 words · 6 min read · ~5 pages · Grade level 14.9 · Accepted 2024-11-26 07:17:53
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 per share SRPT The Nasdaq Global Ma
- $500 million — ill pay Arrowhead an upfront payment of $500 million in cash. Arrowhead has the potential to
- $300.0 million — Arrowhead has the potential to receive $300.0 million in near-term payments associated with t
- $250 million — Arrowhead is eligible to receive up to $250 million in annual fees and, for each of the Pro
- $110.0 million — development milestone payments between $110.0 million and $180.0 million per Program and sale
- $180.0 million — one payments between $110.0 million and $180.0 million per Program and sales milestone payment
- $500.0 million — am and sales milestone payments between $500.0 million and $700.0 million per Program from Sar
- $700.0 million — one payments between $500.0 million and $700.0 million per Program from Sarepta. In addition
- $0.001 — 6,301 shares of common stock, par value $0.001 per share, of Arrowhead (the "Arrowhead
- $325 million — ion, for an aggregate purchase price of $325 million (the "Equity Transaction"). The Arrow
Filing Documents
- d856104d8k.htm (8-K) — 34KB
- 0001193125-24-265627.txt ( ) — 156KB
- srpt-20241124.xsd (EX-101.SCH) — 3KB
- srpt-20241124_lab.xml (EX-101.LAB) — 18KB
- srpt-20241124_pre.xml (EX-101.PRE) — 11KB
- d856104d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Sarepta Therapeutics, Inc. Date: November 26, 2024 By: /s/ Douglas S. Ingram Douglas S. Ingram President and Chief Executive Officer